Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Hematol Oncol Stem Cell Ther ; 14(1): 76-81, 2021 Mar.
Article in English | MEDLINE | ID: mdl-30611712

ABSTRACT

Non-Hodgkin lymphoma (NHL) of the lip is extremely rare. It is usually indolent and in early stages a local approach is often indicated. We present a case report of a patient with extranodal NHL of the lip treated with chemotherapy and low-dose radiation treatment (RT). The patient was affected by B-cell NHL of the marginal zone, Stage IAE. After a few months of observation with progressive disease, the patient was submitted to two cycles of chemotherapy with no response. Therefore, he was treated with very low-dose RT consisting of two fractions of 2 Gy. Complete response was observed and after 1-year follow-up, persistent complete response was recorded. In cases of localized disease, especially in patients with comorbidities of poor performance status (PS), low-dose RT can be an appropriate approach with excellent outcomes in terms of effectiveness and low risk of toxicity.


Subject(s)
Lip Neoplasms/radiotherapy , Lymphoma, B-Cell, Marginal Zone/radiotherapy , Aged, 80 and over , Humans , Lip Neoplasms/metabolism , Lip Neoplasms/pathology , Lymphoma, B-Cell, Marginal Zone/metabolism , Lymphoma, B-Cell, Marginal Zone/pathology , Male , Radiotherapy Dosage
2.
Neuropharmacology ; 57(5-6): 523-30, 2009.
Article in English | MEDLINE | ID: mdl-19628000

ABSTRACT

We investigated the effects of salvinorin A on the basal and the 12 mM K(+)-evoked release of preloaded [(3)H]noradenaline ([(3)H]NA) and [(3)H]serotonin ([(3)H]5-HT) from mouse hippocampal nerve terminals (synaptosomes), as well as on the basal and 12mM K(+)-evoked release of preloaded [(3)H]dopamine ([(3)H]DA) from mouse striatal and prefrontal cortex (PFc) synaptosomes. Salvinorin A (0.1-1000 nM) failed to affect the basal release of amines, but inhibited the 12 mM K(+)-evoked, Ca(2+)-dependent, exocytotic-like release of [(3)H]5-HT and [(3)H]DA. At the same concentration, salvinorin A facilitated the 12 mM K(+)-evoked, Ca(2+)-dependent, exocytotic-like release of [(3)H]NA. These effects could not be observed in pertussis toxin (PTx) entrapped synaptosomes. The broad spectrum kappa-opioid receptor (KOR) antagonist norbinaltorphimine (norBNI, 1-100 nM) antagonized the inhibition of [(3)H]5-HT and [(3)H]DA exocytosis as well as the facilitation of [(3)H]NA overflow induced by 100 nM salvinorin A. The KOR agonist U69593 (1-100 nM) mimicked salvinorin A in inhibiting [(3)H]5-HT and of [(3)H]DA exocytosis, its effect being prevented by norBNI, but leaving unchanged the K(+)-evoked release of [(3)H]NA. The effects of Salvinorin A on neurotransmitter exocytosis were not prevented by the selective mu opioid (MOR) receptor antagonist CTAP (10-100 nM), whereas facilitation of [(3)H]NA exocytosis, but not inhibition of [(3)H]5-HT and [(3)H]DA K(+)-evoked release, was counteracted by the delta opioid receptor (DOR) antagonist naltrindole (1-100 nM). We conclude that salvinorin A presynaptically modulates central NA, 5-HT, and DA exocytosis evoked by a mild depolarizing stimulus by acting at presynaptic opioid receptors having different pharmacological profiles.


Subject(s)
Central Nervous System Agents/pharmacology , Diterpenes, Clerodane/pharmacology , Exocytosis/drug effects , Neurotransmitter Agents/metabolism , Presynaptic Terminals/drug effects , Animals , Calcium/metabolism , Corpus Striatum/drug effects , Corpus Striatum/physiology , Dopamine/metabolism , Exocytosis/physiology , Hippocampus/drug effects , Hippocampus/physiology , Male , Mice , Narcotic Antagonists , Neurons/drug effects , Neurons/physiology , Norepinephrine/metabolism , Potassium/metabolism , Prefrontal Cortex/drug effects , Prefrontal Cortex/physiology , Presynaptic Terminals/physiology , Receptors, Opioid/metabolism , Serotonin/metabolism , Synaptosomes/drug effects , Synaptosomes/physiology
SELECTION OF CITATIONS
SEARCH DETAIL